Latest Nasdaq News

Elevra Lithium's updated scoping study for its North American Lithium mine expansion reveals a faster ramp-up to 338 ktpa spodumene concentrate with stable costs and a significant increase in project value.

Almonty Industries reported a 221% jump in Q1 2026 revenue to CAD 25.4 million, driven by soaring tungsten prices and ramp-up at its Sangdong Mine, while net loss narrowed to CAD 5.3 million amid strong operational cash flow.

Life360 surged to $143.1 million in Q1 2026 revenue, powered by 27% growth in paying subscribers and a 329% jump in advertising following the Nativo acquisition. The company raised its full-year guidance as it navigates temporary user growth headwinds.

Elevra Lithium has struck a US$71 million deal to offload its Ghanaian Ewoyaa Project interest to Zhejiang Huayou Cobalt, pivoting its strategy firmly towards North American assets while shedding funding obligations tied to Ewoyaa.

News Corporation reported a 9% revenue increase to $2.185 billion in Q3 FY2026, driven by growth across its media and real estate segments, but net income attributable to stockholders declined 14% amid rising costs and restructuring.

Jindalee Lithium has locked in a strongly supported A$11 million capital raise through a placement and entitlement offer to fund its McDermitt Lithium Project and the proposed NASDAQ listing of US Elemental Inc.

European Lithium (ASX: EUR) and Critical Metals Corp (NASDAQ: CRML) have agreed to prolong their exclusivity period to finalise a binding scheme of arrangement. The proposed deal would see CRML acquire 100% of EUR's shares and listed options, with EUR shareholders receiving CRML shares at a fixed exchange ratio.

European Lithium (ASX: EUR) has affirmed its compliance with ASX continuous disclosure rules following its announcement of a non-binding merger proposal with Critical Metals Corp. (CRML). The company detailed its negotiation timeline and rationale for the timing of its market disclosures.

LTR Pharma highlights SPONTAN's 5x faster absorption and validated safety, backed by over 1,000 Australian prescriptions and strategic partnerships as it targets FDA approval and US market entry.

Mesoblast Limited posted US$30.3 million in net revenues for Ryoncil® in Q3 2026, hitting key clinical milestones and securing new technology licenses that could boost its next-generation cell therapies.

Ioneer Ltd has raised US$50 million to push forward its fully permitted Rhyolite Ridge lithium-boron project in Nevada, buoyed by a federal court ruling upholding project approvals and ongoing strategic partner discussions.

Reach Resources has boosted its Blue Heaven gold resource by roughly 30% to 80,000 ounces, supported by strong metallurgical results and a newly granted mining lease, while progressing a $3.15 million rights issue to fund further exploration and development.